Novo Nordisk A/S
The Market Access Manager role involves shaping how Novo's obesity pipeline reaches patients in Switzerland by developing and executing local access strategies. The position requires turning global direction into local plans, leading pricing and reimbursement submissions to the Federal Office of Public Health, and collaborating with cross-functional teams and external stakeholders. The role focuses on securing timely, sustainable access to treatment for people living with obesity through strategic planning and evidence-based decision-making.
Headquarters
Alle, Central Jutland, Denmark
Company Size
10001+ employees
Founded
1923
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark, with the stated purpose of driving change to defeat diabetes and other serious chronic diseases. It researches, develops, manufactures and markets pharmaceutical products and medical devices across diabetes care, obesity, haemophilia, growth disorders and other endocrine conditions, and is widely known for its insulin and GLP‑1 therapies. Combining extensive R&D, large‑scale manufacturing and global commercial reach, Novo Nordisk emphasizes patient‑centred care, access programs and sustainability in its work to improve outcomes for people with chronic disease.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Novo Nordisk A/S.
Novo Nordisk A/S didn’t post a salary, so this is our estimate from similar listings.